Retatrutide Triple-Agonist Update: FDA Panel Vote and Metabolic Stacker Access
A 2024 FDA panel vote on peptide classification could reshape retatrutide access for research. This update examines the triple agonist's evidence
Read More →INSIGHTS • UPDATES • EDUCATION
Dallas Peptides
BLOG & LEARNING HUB
WELCOME TO THE DALLAS PEPTIDES
BLOG & LEARNING HUB
More than just peptides. Dallas Peptides is a platform for knowledge and progress. Stay informed with expert insights, research updates, protocols, and everything you need to stay ahead in peptide science.
Latest Articles
Tesamorelin for Visceral Fat: FDA Panel Votes and Access Amid GLP-1 Warnings
Tesamorelin's role in visceral fat reduction faces a turning point as an FDA panel vote could expand access, even as GLP-1 compounding warnings raise
Read More →Retatrutide and Tesamorelin for Visceral Fat: Research Under FDA Scrutiny
Research on retatrutide and tesamorelin for visceral fat reduction is growing, but FDA scrutiny of compounding practices raises safety concerns. This
Read More →Retatrutide vs. Semaglutide for Visceral Fat Loss: Phase 2 Data and Body Recomposition
Phase 2 data on retatrutide, a triple-hormone agonist, suggest greater weight loss than semaglutide, but its impact on visceral fat and body recomp...
Read More →
Peptides: Small Molecules Big Impact
Peptides are among the most fascinating molecules in modern science and wellness. Despite their small size, these compounds pack a powerful punch w...
Read More →
Why Peptide Therapy Is the Ultimate Anti-Aging Treatment?
As we age, our bodies naturally produce fewer peptides—the building blocks of proteins that keep our skin firm, our muscles strong, and our cells f...
Read More →